These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 8458187

  • 1. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA.
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Structural-functional interactions in the therapeutic response of diabetic neuropathy.
    Sima AA, Greene DA.
    Diabet Med; 1993 Mar; 10 Suppl 2():33S-34S. PubMed ID: 8334838
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB, Herold K, Bartkus C.
    Am J Med; 1985 Nov 15; 79(5A):24-37. PubMed ID: 3000176
    [Abstract] [Full Text] [Related]

  • 7. The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.
    Kamijo M, Cherian PV, Sima AA.
    Diabetologia; 1993 Oct 15; 36(10):893-8. PubMed ID: 8243866
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB, Towle VL, Maselli R, Herold K.
    Metabolism; 1986 Apr 15; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [Abstract] [Full Text] [Related]

  • 10. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA, Prashar A, Zhang WX, Chakrabarti S, Greene DA.
    J Clin Invest; 1990 May 15; 85(5):1410-20. PubMed ID: 2110189
    [Abstract] [Full Text] [Related]

  • 11. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IA, Corrall RJ.
    Diabet Med; 1988 Sep 15; 5(6):537-42. PubMed ID: 2974776
    [Abstract] [Full Text] [Related]

  • 12. Effects of aldose reductase inhibitors on the progression of nerve damage.
    Greene DA, Sima AA.
    Diabet Med; 1993 Sep 15; 10 Suppl 2():31S-32S. PubMed ID: 8334837
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
    Jaspan J.
    Drugs; 1986 Sep 15; 32 Suppl 2():23-9. PubMed ID: 2431859
    [Abstract] [Full Text] [Related]

  • 14. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG, O'Brien IA, Morgan MH, Corrall RJ.
    Diabetologia; 1984 Jun 15; 26(6):445-8. PubMed ID: 6432615
    [Abstract] [Full Text] [Related]

  • 15. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE, Larsen AB, Gregersen G.
    Ugeskr Laeger; 1987 Nov 09; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract] [Full Text] [Related]

  • 16. Clinical trials of sorbinil on nerve function.
    Pfeifer MA.
    Metabolism; 1986 Apr 09; 35(4 Suppl 1):78-82. PubMed ID: 3083211
    [Abstract] [Full Text] [Related]

  • 17. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
    Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte D.
    N Engl J Med; 1983 Jan 20; 308(3):119-25. PubMed ID: 6401351
    [Abstract] [Full Text] [Related]

  • 18. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.
    Sima AA, Nathaniel V, Prashar A, Bril V, Greene DA.
    Diabetes; 1991 Sep 20; 40(9):1090-9. PubMed ID: 1936616
    [Abstract] [Full Text] [Related]

  • 19. Axo-glial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat.
    Sima AA, Lattimer SA, Yagihashi S, Greene DA.
    J Clin Invest; 1986 Feb 20; 77(2):474-84. PubMed ID: 3003160
    [Abstract] [Full Text] [Related]

  • 20. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
    Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, Yagihashi S.
    J Diabetes Complications; 1994 Feb 20; 8(1):27-32. PubMed ID: 8167384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.